Overview

hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The null hypothesis of no difference in CR% at 3 months between the arms will be tested against the alternative of a difference in CR% at an alpha level of .05 by assessing the odds ratio for arm yielded by this model.
Phase:
Phase 3
Details
Lead Sponsor:
European Group for Blood and Marrow Transplantation
European Society for Blood and Marrow Transplantation
Collaborators:
Novartis
Pfizer